Dana-Farber Cancer Institute, Boston, MA
Philip Daniel Poorvu , Shari I. Gelber , Shoshana M. Rosenberg , Kathryn Jean Ruddy , Rulla Tamimi , Jeffrey M. Peppercorn , Lidia Schapira , Virginia F. Borges , Steven E. Come , Laura C. Collins , Ellen Warner , Ann H. Partridge
Background: The Oncotype Dx Recurrence Score (RS) predicts distant recurrence risk and benefit from chemotherapy for women with early-stage estrogen receptor (ER) positive (+)/human epidermal growth factor receptor 2 (HER2) negative (-) breast cancer (BC). Due to the independent risk of young age and small proportion of young women in the validation studies, providers may be hesitant to rely on the RS among young women. Methods: Using a multi-center, prospective cohort study of women newly diagnosed with BC at age ≤40 years enrolled from 2006-2016, we identified participants with stage I-III, ER+/HER2- BC. Clinical data were obtained through patient surveys and medical record review. Factors associated with RS testing by univariable analyses (p < 0.20) were used to generate a multivariable logistic regression model. Results: 182 (32%) of 575 eligible women had a RS performed (Table 1). Younger women (ORage ≤30 vs 36-40= 0.49, p = 0.03) and those with larger (OR> 2cm vs ≤2cm= 0.54, p = 0.007), node positive (ORpos vs neg= 0.14, p < 0.0001) or high grade tumors (ORhigh vs low/intermediate= 0.37, p < 0.0001) were less likely to have a RS performed. Of women who had a RS performed, chemotherapy usage was 21/88 (24%), 44/77 (57%), and 17/17 (100%) among those with low, intermediate, and high RS, respectively. Most women with low risk RS who received chemotherapy had other low risk features: 67% T1, 67% N0, and 86% low/intermediate grade. Conclusions: Despite the development of multigene testing to assess the benefit of chemotherapy, many young women with node-negative ER+/HER2- BC are not tested, and when tested, a substantial percentage receive chemotherapy despite a low RS. This highlights an opportunity to improve individualized care for young women with BC.
RS/N (%) | OR (95% CI) | p-value | |
---|---|---|---|
Age ≤30 | 18/75 (24) | 0.49 (0.26,0.93) | 0.03 |
31-35 | 48/158 (30) | 0.87 (0.55,1.34) | 0.57 |
36-40 | 116/342 (34) | Ref | |
Tumor size ≤ 2cm | 137/326 (42) | Ref | |
> 2cm | 45/249 (18) | 0.54 (0.35,0.85) | 0.007 |
Nodal status N0 | 154/322 (48) | Ref | |
N+ | 25/249 (10) | 0.14 (0.09,0.24) | < 0.0001 |
Grade Low/Intermediate | 146/357 (41) | Ref | |
High | 35/213 (16) | 0.37 (0.24,0.59) | < 0.0001 |
* Missing data and factors not associated with RS testing not included
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2021 ASCO Annual Meeting
First Author: Erika P. Hamilton
2017 ASCO Annual Meeting
First Author: Nusayba Ali Bagegni
2023 ASCO Annual Meeting
First Author: Ann Collier
2023 ASCO Annual Meeting
First Author: Mafalda Oliveira